In per-share terms, Takeda would fork over 0.839 new Takeda shares and $30.33 in cash for each Shire share. Date the transaction 1/8/2019. Takeda Pharmaceutical Company (Takeda)/Shire – $58.6 billion. For example if you owned 100 Shire shares then enter. In January of last year, Takeda announced that it completed its M&A of Shire to expand its global biopharmaceutical capabilities headquartered in Japan. This will be 5.034 x (# of Shire shares owned). 503.4 Takeda shares purchased (5.034 x 100). The Takeda-Shire merged company will make it the Number 10 biopharmaceutical company by revenue, with Number 1 being Johnson & Johnson with $76.5 billion in annual revenue and the newly merged Bristol-Myers Squibb-Celgene as Number 9 with $33.8 billion. Under the terms of the acquisition, each Shire shareholder will be entitled to receive $30.33 in cash for each Shire share … Takeda-Shire is projected to have a combined revenue of $33.6 billion. I also have a question regarding the 01/08/2019 merger between Shire and Takeda. Enter a buy transaction for the number of Takeda shares entitled to receive in this merger. Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and Shire plc (LON: SHP) (“Shire”) today announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire.

Takeda is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. 3.

OSAKA, JAPAN, January 8, 2019 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its acquisition of Shire plc (“Shire”), becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. 1099B was issued by Citibank. The total purchase price will be the amount remaining in the Suspense account, if the Suspense balance was zero when this process was …

The acquisition of the Takeda shares is shown as a loss but the cost basis of the sale of the Shire shares is shown as $0.